A randomised clinical trial investigating the effect of canakinumab versus placebo in Stable Post-myocardial Infarction Patients With Elevated hsCRP
| Studied treatment | Quarterly Subcutaneous Canakinumab 50mg, 150mg, 300mg for 36 months |
| Control treatment | placebo |
| Patients | Stable Post-myocardial Infarction Patients With Elevated hsCRP |
| Size | 10066 |
| Blindness | double-blind | Inclusion period | apr 2011 - |
| Follow-up duration | 36 months | Centers | |
| Lost to FU | geographical localisation | ||
| Primary endpoint | cardiovascular events | Design | |
| PeriodeInclusion | apr 2011 - |
On June the 22th, 2017, the sponsor announced that Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis
Ridker PM, Thuren T, Zalewski A, Libby P Interleukin-1? inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605 [PMID: 21982649] link to pdf add to Mendeley
Links
ClinicalTrial.gov record NCT01327846
Comment: On June the 22th, 2017, the sponsor announced that Phase III CANTOS study met the primary endpoint, a composite of heart attack, stroke and cardiovascular death, showing that ACZ885 (canakinumab) in combination with standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis
Appears in following systematic reviews:
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
